Performance of urinary markers in patients with suspicious cystoscopy during follow-up of recurrent non-muscle invasive bladder cancer: BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, CancerCheck® UBC® rapid VISUAL, and uromonitor® in comparison to cytology

• Published in: Urology (Ridgewood, N.J.) N.J.), 2024-12
• Main Authors: Ecke, Thorsten H., Meisl, Christina J., Schlomm, Thorsten, Rabien, Anja, Labonté, Flora, Rong, Dezhi, Hofbauer, Sebastian, Friedersdorff, Frank, Sommerfeldt, Lilli, Gagel, Nella, Gössl, Andreas, Barski, Dimitri, Otto, Thomas, Grunewald, Camilla M., Niegisch, Günter, Hennig, Martin J.P., Kramer, Mario W., Koch, Stefan, Roggisch, Jenny, Weiß, Sarah, Waldner, Michael, Graff, Johannes, Veltrup, Elke, Linden, Friederike, Hake, Roland, Eidt, Sebastian, Wirtz, Ralph M., Klatte, Tobias
• Format: Article
• Language: English
• ISSN: 0090-4295; 1527-9995; 1527-9995
• DOI: 10.1016/j.urology.2024.11.056

To compare all available rapid tests on a large cohort of recurrent bladder cancer during follow-up in this multicentre-study is the first study. BTA stat®, NMP22® BladderChek®, UBC® Rapid Test CancerCheck® UBC® rapid VISUAL, and uromonitor® are urinary based rapid tests for bladder cancer detection. In total 187 urine samples were analysed from patients with suspected recurrent non-muscle invasive urothelial bladder cancer on cystoscopy during follow-up in a real-world assessment. All suspicious lesions were resected with 110 samples showing recurrent urothelial cancer. Urine samples were analysed by the BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, CancerCheck® UBC® rapid VISUAL, uromonitor®, and cytology. Sensitivities and specificities were calculated by contingency analyses. All investigated urinary markers could detect a higher percentage of pathological results in urine of bladder cancer patients compared to urine of tumor free patients. The calculated diagnostic sensitivities for BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, CancerCheck® UBC® rapid VISUAL, uromonitor®, and cytology were 60.0%, 10.0%, 58.0%, 32.0%, 54.5%, and 41.5% for non-muscle invasive low-grade, and 64.0%, 40.0%, 77.8%, 50.0%, 56.0%, and 65.5% for non-muscle invasive high-grade bladder cancer. The specificity was 51.3%, 94.8%, 66.2%, 89.5%, 94.9%, and 66.2%, respectively. During follow-up sensitivities and specificities of most urinary markers are higher compared to cytology for the detection of recurrent bladder cancer. BTA stat®, UBC® Rapid Test, and uromonitor® appear useful in this setting.